U.S. Physicians Trade Insurance Red Tape for Canadian Winters, and Blockbuster Drugs Finally Lose Their Monopolies, and SaaS Vendors Cash In on the 340B Compliance Nightmare

Hi All,

Happy Tuesday! Whether we are watching physicians flee to the frozen tundras of Canada to escape the soul-crushing paperwork of corporate medicine or seeing health systems buy expensive "regulatory dumpster fire" software just to navigate 340B drug discounts, it is clear that the American healthcare "system" is now just three insurance companies in a trench coat. Even the pharmaceutical giants are feeling the squeeze, forced to finally stop milking their aging blockbuster cash cows and face the terrifying prospect of—god forbid—actually innovating once their patent litigation strategies finally hit a wall in 2026. Ultimately, it seems the only thing more certain than a "patent cliff" is the industry's tireless commitment to finding new, high-tech ways to ensure that providing actual care remains the most difficult part of being a doctor.

Enjoy the rundown!

Jacob Brody (Cofounder & CEO, ZorroRX)

[HEALTH CARE un-covered] Why More U.S. Doctors Are Moving to Canada

Recent data shows a massive surge in U.S. physicians migrating to Canada, with one recruiting agency reporting a 750 percent increase in applicants driven by exhaustion over insurance-related "red tape" and corporate consolidation. These doctors are increasingly willing to accept lower pay in exchange for a single-payer system that eliminates the administrative burden of prior authorizations and ensures patients can access care without facing financial ruin. It turns out that even the sub-zero temperatures of a Manitoba winter are more hospitable than a three-hour lunch break spent begging a billion-dollar insurance conglomerate for permission to treat a sick patient.

Full Article

[Fierce Pharma] The top 10 drugs losing US exclusivity in 2026

The pharmaceutical industry is bracing for a massive revenue shift as ten major blockbuster drugs, including Roche’s Xolair and Merck’s Januvia, face the expiration of key patents throughout 2026. While some manufacturers are scrambling to cut costs or launch "follow-on" treatments to cushion the blow, others are facing a "biosimilar void" where a lack of immediate competitors might temporarily protect their dwindling monopolies. This annual "patent cliff" serves as a critical turning point that forces drugmakers to pivot from milking aging cash cows to actually innovating, or at least finding new ways to litigate their way into 2027. It is truly moving to watch these multi-billion dollar corporations prepare to share the market, though I’m sure their newfound commitment to "generic accessibility" has absolutely nothing to do with the fact that their legal teams finally ran out of ways to stall the inevitable.

Full Article

[On Healthcare] The 340B Software Stack: The Next Healthcare SaaS Vertical

The 340B Drug Pricing Program has evolved from a simple spreadsheet task into a high-stakes data problem, sparking a dedicated SaaS vertical focused on eligibility, split-billing, and manufacturer compliance. As drug manufacturers increasingly restrict contract pharmacy arrangements, sophisticated software layers—utilizing real-time FHIR integration and machine learning—are becoming essential for health systems to capture savings and manage adversarial legal disputes. Considering the program generates tens of billions in annual savings, health systems are more than happy to throw money at any software vendor promising to navigate this regulatory dumpster fire if it means clawing back a few more percentage points of margin.

Full Article